{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:02:22Z","timestamp":1789214542107,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rostock University Medical Center, FORUN grant (no grant number) Rostock School of Oncology, Medical Scientist fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Dysregulation of the intrinsic BCL-2 pathway-mediated apoptosis cascade is a common feature of hematological malignancies including acute B-lymphoblastic leukemia (B-ALL). The\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearranged high-risk cytogenetic subtype is characterized by high expression of antiapoptotic protein BCL-2, likely due to the direct activating binding of\n                    <jats:italic>KMT2A<\/jats:italic>\n                    fusion proteins to the\n                    <jats:italic>BCL2<\/jats:italic>\n                    gene. The BCL-2 inhibitor venetoclax (VEN) has proven great clinical value in other blood cancers, however, data on B-ALL is sparse and past studies have not so far described the effects of VEN on gene and protein expression profiles. Using cell lines and patient-derived in vivo xenograft models, we show BCL-2 pathway-mediated apoptosis induction and decelerated tumor cell counts in\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearranged B-ALL but not in other cytogenetic subtypes. VEN treatment of cell line- and patient-derived xenografts reduced blast frequencies in blood, bone marrow, and spleen, and tumor cell doubling times were increased. Growth rates are further correlated with VEN concentrations in blood. In vitro incubation with VEN resulted in BCL-2 dephosphorylation and targeted panel RNA sequencing revealed reduced gene expression of antiapoptotic pathway members\n                    <jats:italic>BCL2<\/jats:italic>\n                    ,\n                    <jats:italic>MCL1<\/jats:italic>\n                    , and\n                    <jats:italic>BCL2L1<\/jats:italic>\n                    (BCL-XL). Reinforced translocation of BAX proteins towards mitochondria induced caspase activation and cell death commitment. Prolonged VEN application led to upregulation of antiapoptotic proteins BCL-2, MCL-1, and BCL-XL. Interestingly, the extrinsic apoptosis pathway was strongly modulated in SEM cells in response to VEN. Gene expression of members of the tumor necrosis factor signaling cascade was increased, resulting in canonical NF-kB signaling. This possibly suggests a previously undescribed mechanism of BCL-2-independent and NF-kB-mediated upregulation of MCL-1 and BCL-XL. In summary, we herein prove that VEN is a potent option to suppress tumor cells in\n                    <jats:italic>KMT2A<\/jats:italic>\n                    -rearranged B-ALL in vitro and in vivo. Possible evasion mechanisms, however, must be considered in subsequent studies.\n                  <\/jats:p>","DOI":"10.1038\/s41420-022-01093-3","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T01:02:50Z","timestamp":1656637370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effective tumor cell abrogation via Venetoclax-mediated BCL-2 inhibition in KMT2A-rearranged acute B-lymphoblastic leukemia"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-7072","authenticated-orcid":false,"given":"Anna","family":"Richter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Brock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Freitag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anett","family":"Sekora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Knuebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Krohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rico","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2529-0732","authenticated-orcid":false,"given":"Burkhard","family":"Hinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Murua Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","volume":"132","author":"R Valentin","year":"2018","unstructured":"Valentin R, Grabow S, Davids MS. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018;132:1248\u201364.","journal-title":"Blood"},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1038\/sj.onc.1209608","volume":"25","author":"S Fulda","year":"2006","unstructured":"Fulda S, Debatin K-M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 2006;25:4798\u2013811.","journal-title":"Oncogene"},{"key":"1093_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-135","volume":"9","author":"C Krakstad","year":"2010","unstructured":"Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010;9:135.","journal-title":"Mol Cancer"},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","volume":"13","author":"JM Benito","year":"2015","unstructured":"Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, et al. MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199. Cell Rep. 2015;13:2715\u201327.","journal-title":"Cell Rep."},{"key":"1093_CR6","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med"},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134:111\u201322.","journal-title":"Blood"},{"key":"1093_CR8","doi-asserted-by":"publisher","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","volume":"7","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020;7:e724\u2013e736.","journal-title":"Lancet Haematol"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","volume":"20","author":"G Richard-Carpentier","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, et al. Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2020;20:212\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/S0140-6736(19)33018-1","volume":"395","author":"F Malard","year":"2020","unstructured":"Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020;395:1146\u201362.","journal-title":"Lancet"},{"key":"1093_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","volume":"141","author":"BW Robinson","year":"2008","unstructured":"Robinson BW, Behling KC, Gupta M, Zhang AY, Moore JS, Bantly AD, et al. Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation. Br J Haematol. 2008;141:827\u201339.","journal-title":"Br J Haematol"},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","volume":"128","author":"SL Khaw","year":"2016","unstructured":"Khaw SL, Suryani S, Evans K, Richmond J, Robbins A, Kurmasheva RT, et al. Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 2016;128:1382\u201395.","journal-title":"Blood"},{"key":"1093_CR14","doi-asserted-by":"crossref","unstructured":"Seyfried F, Demir S, H\u00f6rl RL, Stirnwei\u00df FU, Ryan J, Scheffold A, et al. Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling. Cell Death Dis. 2019;10:571.","DOI":"10.1038\/s41419-019-1801-0"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","volume":"4","author":"DM Moujalled","year":"2020","unstructured":"Moujalled DM, Hanna DT, Hediyeh-Zadeh S, Pomilio G, Brown L, Litalien V, et al. Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Adv. 2020;4:2762\u20137.","journal-title":"Blood Adv"},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.21873\/invivo.11802","volume":"34","author":"M Massimino","year":"2020","unstructured":"Massimino M, Tirr\u00f2 E, Stella S, Pennisi MS, Vitale SR, Puma A, et al. Targeting BCL-2 as a therapeutic strategy for primary p210BCR-ABL1-positive B-ALL cells. In Vivo. 2020;34:511\u20136.","journal-title":"In Vivo"},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/ng.3362","volume":"47","author":"U Fischer","year":"2015","unstructured":"Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, et al. Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet. 2015;47:1020\u20139.","journal-title":"Nat Genet"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","volume":"75","author":"SE Alford","year":"2015","unstructured":"Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, et al. BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res. 2015;75:1366\u201375.","journal-title":"Cancer Res"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M, Kirchhoff H, Battmer K, Wohlan K, Lee CW, Ricke-Hoch M, et al. Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia. 2019;33:1313\u201323.","journal-title":"Leukemia"},{"key":"1093_CR20","doi-asserted-by":"publisher","first-page":"D613","DOI":"10.1093\/nar\/gkaa1024","volume":"49","author":"M Martens","year":"2021","unstructured":"Martens M, Ammar A, Riutta A, Waagmeester A, Slenter DN, Hanspers K, et al. WikiPathways: connecting communities. Nucleic Acids Res. 2021;49:D613\u2013D621.","journal-title":"Nucleic Acids Res"},{"key":"1093_CR21","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1002\/ccr3.3041","volume":"8","author":"E Zappone","year":"2020","unstructured":"Zappone E, Cencini E, Defina M, Sicuranza A, Gozzetti A, Ciofini S, et al. Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia. Clin Case Rep. 2020;8:2000\u20132.","journal-title":"Clin Case Rep"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1182\/bloodadvances.2021004513","volume":"5","author":"J Lazaro-Navarro","year":"2021","unstructured":"Lazaro-Navarro J, Pimentel-Guti\u00e9rrez HJ, Gauert A, Hagemann AIH, Eisenschmid JL, Goekbuget N, et al. Inhibiting casein kinase 2 sensitizes acute lymphoblastic leukemia cells to venetoclax via MCL1 degradation. Blood Adv. 2021;5:5501\u20136.","journal-title":"Blood Adv"},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12071883","volume":"12","author":"A Gauert","year":"2020","unstructured":"Gauert A, Olk N, Pimentel-Guti\u00e9rrez H, Astrahantseff K, Jensen LD, Cao Y, et al. Fast, in vivo model for drug-response prediction in patients with B-cell precursor acute lymphoblastic leukemia. Cancers. 2020;12:1\u201313.","journal-title":"Cancers"},{"key":"1093_CR24","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","volume":"129","author":"V Frismantas","year":"2017","unstructured":"Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, et al. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood. 2017;129:e26\u2013e37.","journal-title":"Blood"},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1101\/gad.1741408","volume":"22","author":"MG Guenther","year":"2008","unstructured":"Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL, et al. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008;22:3403\u20138.","journal-title":"Genes Dev"},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.celrep.2012.12.016","volume":"3","author":"AC Wilkinson","year":"2013","unstructured":"Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013;3:116\u201327.","journal-title":"Cell Rep."},{"key":"1093_CR27","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.2019004326","volume":"136","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kielbassa K, ter Burg J, Bax DJC, Fernandes SM, Borst J, et al. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood. 2020;136:2918\u201326.","journal-title":"Blood"},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"8750","DOI":"10.18632\/oncotarget.3275","volume":"6","author":"D Chiron","year":"2015","unstructured":"Chiron D, Dousset C, Brosseau C, Touzeau C, Ma\u00efga S, Moreau P, et al. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget. 2015;6:8750\u20139.","journal-title":"Oncotarget"},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/cdd.2016.105","volume":"24","author":"V Peperzak","year":"2017","unstructured":"Peperzak V, Slinger E, Ter Burg J, Eldering E. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ. 2017;24:111\u20139.","journal-title":"Cell Death Differ"},{"key":"1093_CR30","first-page":"e302","volume":"100","author":"R Thijssen","year":"2015","unstructured":"Thijssen R, Slinger E, Weller K, Geest CR, Beaumont T, Van Oers MHJ, et al. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors. Haematologica. 2015;100:e302\u20136.","journal-title":"Haematologica"},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","volume":"28","author":"M Haselager","year":"2021","unstructured":"Haselager M, Thijssen R, West C, Young L, Van Kampen R, Willmore E, et al. Regulation of Bcl-XL by non-canonical NF-\u03baB in the context of CD40-induced drug resistance in CLL. Cell Death Differ. 2021;28:1658\u201368.","journal-title":"Cell Death Differ"},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D\u2019Rozario J, Assouline S, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"e52798","DOI":"10.1371\/journal.pone.0052798","volume":"7","author":"N Terziyska","year":"2012","unstructured":"Terziyska N, Castro Alves C, Groiss V, Schneider K, Farkasova K, Ogris M, et al. In vivo imaging enables high resolution preclinical trials on patients\u2019 leukemia cells growing in mice. PLoS ONE. 2012;7:e52798.","journal-title":"PLoS ONE"},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13045-018-0607-3","volume":"11","author":"C Roolf","year":"2018","unstructured":"Roolf C, Richter A, Konkolefski C, Knuebel G, Sekora A, Krohn S, et al. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J Hematol Oncol. 2018;11:62.","journal-title":"J Hematol Oncol"},{"key":"1093_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5411-0","volume":"19","author":"A Richter","year":"2019","unstructured":"Richter A, Roolf C, Hamed M, Gladbach YS, Sender S, Konkolefski C, et al. Combined casein kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia. BMC Cancer. 2019;19:202.","journal-title":"BMC Cancer"},{"key":"1093_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-6650-9","volume":"20","author":"A Richter","year":"2020","unstructured":"Richter A, Sender S, Lenz A, Schwarz R, Hinz B, Knuebel G, et al. Influence of casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo. BMC Cancer. 2020;20:184.","journal-title":"BMC Cancer"},{"key":"1093_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells11010150","volume":"11","author":"A Richter","year":"2022","unstructured":"Richter A, Roolf C, Sekora A, Knuebel G, Krohn S, Lange S, et al. The molecular subtype of adult acute lymphoblastic leukemia samples determines the engraftment site and proliferation kinetics in patient-derived xenograft models. Cells. 2022;11:1\u201322.","journal-title":"Cells"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01093-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01093-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T10:36:23Z","timestamp":1669286183000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-022-01093-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41420-022-01093-3","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"9 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"302"}}